SGS Invests in New E&L Laboratory in India
SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.
SGS announced on Oct. 12, 2021, that it is investing in a new extractables and leachables (E&L) testing laboratory in Navi Mumbai, India. The lab is set to open by the end of 2021 and will provide testing services for verifying product safety for pharmaceutical, biopharmaceutical, and medical device companies in Southeast Asia.
The new lab will be approximately 3000 ft.2 and will offer a broad spectrum of the latest E&L testing solutions, including:
- gas chromatography–mass spectrometry (GC–MS) and headspace–GC/MS for the analysis of semi-volatile and volatile components
- liquid chromatography with tandem mass spectrometry (LC–MSMS) for the quantitative analysis of trace leachable components
- high resolution LC–MSMS to generate data that supports identification of unknown components
- and inductively coupled plasma–MS to quantitate screening and identification of inorganics.
This laboratory in India will complement SGS's existing testing network. The company has three other E&L centers of excellence located in the United States, Germany, and China.
Source: SGS
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
